Cargando…

Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion

Coronavirus disease 2019 (COVID-19) is rapidly spreading. Researchers around the world are dedicated to finding the treatment clues for COVID-19. Drug repositioning, as a rapid and cost-effective way for finding therapeutic options from available FDA-approved drugs, has been applied to drug discover...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Xiongfei, Shen, Ling, Gao, Pengfei, Huang, Li, Liu, Guangyi, Zhou, Liqian, Peng, Lihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919055/
https://www.ncbi.nlm.nih.gov/pubmed/35295301
http://dx.doi.org/10.3389/fmicb.2022.740382
_version_ 1784668870479446016
author Tian, Xiongfei
Shen, Ling
Gao, Pengfei
Huang, Li
Liu, Guangyi
Zhou, Liqian
Peng, Lihong
author_facet Tian, Xiongfei
Shen, Ling
Gao, Pengfei
Huang, Li
Liu, Guangyi
Zhou, Liqian
Peng, Lihong
author_sort Tian, Xiongfei
collection PubMed
description Coronavirus disease 2019 (COVID-19) is rapidly spreading. Researchers around the world are dedicated to finding the treatment clues for COVID-19. Drug repositioning, as a rapid and cost-effective way for finding therapeutic options from available FDA-approved drugs, has been applied to drug discovery for COVID-19. In this study, we develop a novel drug repositioning method (VDA-KLMF) to prioritize possible anti-SARS-CoV-2 drugs integrating virus sequences, drug chemical structures, known Virus-Drug Associations, and Logistic Matrix Factorization with Kernel diffusion. First, Gaussian kernels of viruses and drugs are built based on known VDAs and nearest neighbors. Second, sequence similarity kernel of viruses and chemical structure similarity kernel of drugs are constructed based on biological features and an identity matrix. Third, Gaussian kernel and similarity kernel are diffused. Forth, a logistic matrix factorization model with kernel diffusion is proposed to identify potential anti-SARS-CoV-2 drugs. Finally, molecular dockings between the inferred antiviral drugs and the junction of SARS-CoV-2 spike protein-ACE2 interface are implemented to investigate the binding abilities between them. VDA-KLMF is compared with two state-of-the-art VDA prediction models (VDA-KATZ and VDA-RWR) and three classical association prediction methods (NGRHMDA, LRLSHMDA, and NRLMF) based on 5-fold cross validations on viruses, drugs, and VDAs on three datasets. It obtains the best recalls, AUCs, and AUPRs, significantly outperforming other five methods under the three different cross validations. We observe that four chemical agents coming together on any two datasets, that is, remdesivir, ribavirin, nitazoxanide, and emetine, may be the clues of treatment for COVID-19. The docking results suggest that the key residues K353 and G496 may affect the binding energies and dynamics between the inferred anti-SARS-CoV-2 chemical agents and the junction of the spike protein-ACE2 interface. Integrating various biological data, Gaussian kernel, similarity kernel, and logistic matrix factorization with kernel diffusion, this work demonstrates that a few chemical agents may assist in drug discovery for COVID-19.
format Online
Article
Text
id pubmed-8919055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89190552022-03-15 Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion Tian, Xiongfei Shen, Ling Gao, Pengfei Huang, Li Liu, Guangyi Zhou, Liqian Peng, Lihong Front Microbiol Microbiology Coronavirus disease 2019 (COVID-19) is rapidly spreading. Researchers around the world are dedicated to finding the treatment clues for COVID-19. Drug repositioning, as a rapid and cost-effective way for finding therapeutic options from available FDA-approved drugs, has been applied to drug discovery for COVID-19. In this study, we develop a novel drug repositioning method (VDA-KLMF) to prioritize possible anti-SARS-CoV-2 drugs integrating virus sequences, drug chemical structures, known Virus-Drug Associations, and Logistic Matrix Factorization with Kernel diffusion. First, Gaussian kernels of viruses and drugs are built based on known VDAs and nearest neighbors. Second, sequence similarity kernel of viruses and chemical structure similarity kernel of drugs are constructed based on biological features and an identity matrix. Third, Gaussian kernel and similarity kernel are diffused. Forth, a logistic matrix factorization model with kernel diffusion is proposed to identify potential anti-SARS-CoV-2 drugs. Finally, molecular dockings between the inferred antiviral drugs and the junction of SARS-CoV-2 spike protein-ACE2 interface are implemented to investigate the binding abilities between them. VDA-KLMF is compared with two state-of-the-art VDA prediction models (VDA-KATZ and VDA-RWR) and three classical association prediction methods (NGRHMDA, LRLSHMDA, and NRLMF) based on 5-fold cross validations on viruses, drugs, and VDAs on three datasets. It obtains the best recalls, AUCs, and AUPRs, significantly outperforming other five methods under the three different cross validations. We observe that four chemical agents coming together on any two datasets, that is, remdesivir, ribavirin, nitazoxanide, and emetine, may be the clues of treatment for COVID-19. The docking results suggest that the key residues K353 and G496 may affect the binding energies and dynamics between the inferred anti-SARS-CoV-2 chemical agents and the junction of the spike protein-ACE2 interface. Integrating various biological data, Gaussian kernel, similarity kernel, and logistic matrix factorization with kernel diffusion, this work demonstrates that a few chemical agents may assist in drug discovery for COVID-19. Frontiers Media S.A. 2022-02-28 /pmc/articles/PMC8919055/ /pubmed/35295301 http://dx.doi.org/10.3389/fmicb.2022.740382 Text en Copyright © 2022 Tian, Shen, Gao, Huang, Liu, Zhou and Peng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Tian, Xiongfei
Shen, Ling
Gao, Pengfei
Huang, Li
Liu, Guangyi
Zhou, Liqian
Peng, Lihong
Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion
title Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion
title_full Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion
title_fullStr Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion
title_full_unstemmed Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion
title_short Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion
title_sort discovery of potential therapeutic drugs for covid-19 through logistic matrix factorization with kernel diffusion
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919055/
https://www.ncbi.nlm.nih.gov/pubmed/35295301
http://dx.doi.org/10.3389/fmicb.2022.740382
work_keys_str_mv AT tianxiongfei discoveryofpotentialtherapeuticdrugsforcovid19throughlogisticmatrixfactorizationwithkerneldiffusion
AT shenling discoveryofpotentialtherapeuticdrugsforcovid19throughlogisticmatrixfactorizationwithkerneldiffusion
AT gaopengfei discoveryofpotentialtherapeuticdrugsforcovid19throughlogisticmatrixfactorizationwithkerneldiffusion
AT huangli discoveryofpotentialtherapeuticdrugsforcovid19throughlogisticmatrixfactorizationwithkerneldiffusion
AT liuguangyi discoveryofpotentialtherapeuticdrugsforcovid19throughlogisticmatrixfactorizationwithkerneldiffusion
AT zhouliqian discoveryofpotentialtherapeuticdrugsforcovid19throughlogisticmatrixfactorizationwithkerneldiffusion
AT penglihong discoveryofpotentialtherapeuticdrugsforcovid19throughlogisticmatrixfactorizationwithkerneldiffusion